ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

POLB Poolbeg Pharma Plc

12.80
0.00 (0.00%)
17 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Poolbeg Pharma Plc LSE:POLB London Ordinary Share GB00BKPG7Z60 ORD 0.02P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 12.80 12.60 13.00 12.80 12.60 12.60 875,875 11:13:30
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Coml Physical, Biologcl Resh 0 -4.69M -0.0094 -13.62 64M
Poolbeg Pharma Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker POLB. The last closing price for Poolbeg Pharma was 12.80p. Over the last year, Poolbeg Pharma shares have traded in a share price range of 6.55p to 15.70p.

Poolbeg Pharma currently has 500,000,000 shares in issue. The market capitalisation of Poolbeg Pharma is £64 million. Poolbeg Pharma has a price to earnings ratio (PE ratio) of -13.62.

Poolbeg Pharma Share Discussion Threads

Showing 2726 to 2750 of 3350 messages
Chat Pages: Latest  110  109  108  107  106  105  104  103  102  101  100  99  Older
DateSubjectAuthorDiscuss
05/12/2023
10:18
this is no more than a summary of what we know
ali47fish
05/12/2023
08:46
Poolbeg Pharma featured in Business Post article, which discusses the ambition to repeat the success of Amryt Pharma:https://twitter.com/PoolbegPharma/status/1731935291827499264
burtond1
30/11/2023
07:06
Out with the old, in with the new.

Thanks and au revoir, Patrick

lfdkmp
24/11/2023
11:45
Wow, looking positive
chezt
24/11/2023
11:08
Through 10p. Great to see.
rafboy
23/11/2023
18:56
I can easily see egg on my face and a saddened expression as a non holder, agreed.
zero the hero
23/11/2023
17:05
Zero there was a chance to buy back in at 8.5p after the first rise, however it has been fairly strong since, around the 9.5p level.
I bought another two tranches today at 9.5p and came back to see several more buys since then.
I understand people taking a profit and maybe even trading elsewhere in the meantime, but there seems to be strength here and with the new Directors coming aboard shortly I think we will hear more and more....

troutisout
23/11/2023
14:50
Still out of this one biding my time, will probably buy back in at some point as it looks to have a good future. If I get caught "out" by a good RNS, so be it. I tried holding long on other companies in the past but the recent AIM climate does not reward holding ... adapt, and try and trade on good news / spikes.
zero the hero
21/11/2023
16:34
In case you missed our webinar with Poolbeg Pharma (POLB), the recording can be found on our YouTube channel:
sharesoc
21/11/2023
07:35
More good news for #POLB They have been notified by the Japanese Patent Office of their official decision to grant the Immunomodulator II patent application for POLB 001, further strengthening their robust intellectual property in this territory. By continuing to strategically grow the IP around POLB 001 they aim to enhance the overall value of this exciting molecule for partnering purposes. https://www.londonstockexchange.com/news-article/POLB/immunomodulator-ii-patent-granted-in-japan/16217595
burtond1
20/11/2023
10:58
This is interesting from the latest POLB 001 Oncology Update presentation:https://twitter.com/PoolbegPharma/status/1726508831105274199 The snippet features a patient's perspective & discusses Bob Munro's journey. Bob has entered remission after 12 years of treatment and highlights how these drugs seem to be game-changers for the world of cancer. However, he suffered many setbacks due the side effects associated with these breakthrough treatments and notes how CRS (Cytokine Release Syndrome) can massively impact a patient's journey and quality of life when dealing with cancer.
burtond1
17/11/2023
12:10
Some nice buys today supporting the SP
inaminute
16/11/2023
21:29
Inaminute,
"serious investors"

Who are these serious investors? You obviously know them as they your mates, so name them? You won't because you're trying to pull the wool over readers eyes.

Readers can then check for themselves whether they are credible.

sikhthetech
16/11/2023
21:27
Readers can see the evidence for themselves.


sikhthetech - 02 Mar 2023 - 11:35:06 - 2229 of 2739 Poolbeg Pharma - POLB
CF used to present good presentations did he?.

As of latest published results, Polb had ZERO revenues, yet £1.2m admin costs.

The access to HVO data is currently Free but Polb will start paying for it in 6 months time.

Mcap £52m with jam tomorrow.



sikhthetech - 15 Nov 2022 - 14:56:15 - 1542 of 1728 Poolbeg Pharma - POLB
elrico,

Are you denying these are the latest company results? Really?

Mcap of £50m for a company which reported ZERO revenue and significant costs.
It's all jam tomorrow.

revenues ZERO
Admin expenses £1.2m

sikhthetech
16/11/2023
18:08
Just ignore. Turns up like a bad smell and as you say has zero credibility amongst any serious investors. Best not to give oxygen to
inaminute
16/11/2023
16:39
Sikh I find it highly amusing you still think you have any credibility whatsoever. You clearly have no idea about investing. How's Totally doing?
ironman22
16/11/2023
16:07
Burton,

Why is it really good news? Please explain how much they will earn from this?


£47m for a company with ZERO revenues, HAD £1.2m admin costs which will increase due due to recent senoir appointees. Plus they now have to pay HVO for accessing the data.

The cash is from their placing.

£47m for jam tomorrow.

As Chica's previous post, pump and dump.


I noticed 1gw and his mates are quiet about the presentation and today's news. You have to wonder why? .

sikhthetech
16/11/2023
09:12
Really good news this for #POLB https://www.londonstockexchange.com/news-article/POLB/polb-001-lps-trial-data-to-be-presented-at-iuis/16211943Poolbeg abstract will be presented at the prestigious 18th International Congress of Immunology in Cape town later this month. The presentation will provide insight into the positive results from the POLB 001 LPS human challenge trial and its acceptance by IUIS truly underscores the potential of POLB 001 as a groundbreaking therapy for the Cytokine Release Syndrome (CRS) in oncology as well as severe influenza.
burtond1
16/11/2023
07:24
good rns on presentatiom of polb in an important form -will it raise the needle
ali47fish
15/11/2023
17:46
A great recovery here today, I am happy to have a reasonable investment in this business. They have plenty of cash and in this environment it put's you in a very strong position, especially with CF up there at the top !! GLA
parsons4
15/11/2023
11:24
Nice strength here
inaminute
14/11/2023
15:02
I bet Elrico and his Guild cronies made a chunk of change pumping it to 'Lemmings' over the last few weeks.
He'd been pumping it 'big time' on both forums!



elrico - 09 Nov 2023 - 13:31:28 - 2690 of 2732
Excited! #POLB announces former #AmrytPharma execs are joining Poolbeg Pharma leadership! With their proven track record, could repeat building a $billion-dollar biopharma💡🔬 #biotech
elrico - 08 Nov 2023 - 11:55:21 - 2680 of 2732
We have produced a broad overview for ease of ref for investors of the IMC featuring the exciting #POLB 001 Oncology Programme.




elrico - 03 Nov 2023 - 17:58:53 - 18343 of 18347
This post belongs to a guild - only members can see it. Join elrico Guilds to see it.
elrico - 03 Nov 2023 - 00:42:42 - 18342 of 18347
This post belongs to a guild - only members can see it. Join elrico Guilds to see it.
elrico - 03 Nov 2023 - 00:40:59 - 18341 of 18347
This post belongs to a guild - only members can see it. Join elrico Guilds to see it.
elrico - 01 Nov 2023 - 13:29:27 - 2665 of 2732
Poolbeg Pharma PLC 📢 Poolbeg Pharma, focused on diseases with high unmet needs, is hosting an investors & analysts meeting on the POLB 001 Oncology Programme. Our main research emphasis? Tackling Cytokine Release Syndrome (CRS) - a major challenge in cancer immunotherapy treatments.


elrico - 29 Oct 2023 - 14:06:20 - 2648 of 2732
Poolbeg Pharma is on a mission to revolutionize metabolic condition treatment with an innovative oral drug. With strategic partnerships and funding in the pipeline, they're set to make a big impact and preserve their strong cash reserves of £14.1M as of June 30, 2023.

chica1
14/11/2023
13:14
The old 50% pull back. Sadly these days feel more like 75%! Should see some support at 8 and a lot of support at 7 were it to fall that far
discojames
14/11/2023
12:34
Any now like all stocks that trade on this dodgy AIM exchange (once they've sucked in more lemmings,who will eventually sell at a loss and perpetuate)the slow decline downwards!

Nothing to do with Poolbeg it pretty much happens all shares on the AIM.

chica1
13/11/2023
08:56
Miss the IMC presentation last weekend??Trying to work out why shares are up over 30% in a week??Have a watch if this. The move has only just started!! #PILB shared the full recording of Friday's IMC presentation on Twitter:https://twitter.com/PoolbegPharma/status/1723971941025841628
burtond1
Chat Pages: Latest  110  109  108  107  106  105  104  103  102  101  100  99  Older